Xtant Medical more than doubled the capacity of its tissue processing facility in Montana with the addition of seven new processing rooms.
The new suite will support an increase in processing volume and a reduction in time required to get processing suites available for reuse.
In its 1Q16 revenue call, the company had noted that a record 4Q15 had depleted finished goods inventory by year-end; as of the call, 3Demin and OsteoSelect biologic products continued to be on allocation. However, leadership noted that as additional supply becomes available, 3Demin could generate revenue of $5MM to $6MM per quarter, similar to OsteoSponge revenue.
Xtant Medical more than doubled the capacity of its tissue processing facility in Montana with the addition of seven new processing rooms.
The new suite will support an increase in processing volume and a reduction in time required to get processing suites available for reuse.
In its 1Q16 revenue call, the company had noted that a...
Xtant Medical more than doubled the capacity of its tissue processing facility in Montana with the addition of seven new processing rooms.
The new suite will support an increase in processing volume and a reduction in time required to get processing suites available for reuse.
In its 1Q16 revenue call, the company had noted that a record 4Q15 had depleted finished goods inventory by year-end; as of the call, 3Demin and OsteoSelect biologic products continued to be on allocation. However, leadership noted that as additional supply becomes available, 3Demin could generate revenue of $5MM to $6MM per quarter, similar to OsteoSponge revenue.
Copy to clipboard 
